China-Based Zhifei Biological Partners With GSK To Expand Shingrix Vaccine Access Across China Via £2.5B Deal
Portfolio Pulse from Vandana Singh
GSK plc has entered into an exclusive agreement with Chongqing Zhifei Biological Products to co-promote GSK's shingles vaccine, Shingrix, in China. The deal, worth £2.5 billion over three years, will significantly extend the availability of Shingrix in China. Zhifei will have exclusive rights to import and distribute Shingrix in China from January 2024. The partnership is expected to support GSK's goal of doubling global Shingrix sales to more than £4 billion by 2026.
October 09, 2023 | 3:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The partnership with Zhifei Biological is expected to significantly boost GSK's Shingrix sales in China, supporting the company's goal of doubling global Shingrix sales by 2026. The deal is worth £2.5 billion over three years.
The partnership with Zhifei Biological, the largest Chinese vaccine company by revenue, provides GSK with a significant opportunity to expand the reach of its Shingrix vaccine in China. This is expected to boost GSK's revenues and support its goal of doubling global Shingrix sales by 2026. The deal is worth £2.5 billion over three years, which is a substantial revenue source for GSK.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100